Drug Profile
AIT 110
Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator Spectrum Pharmaceuticals
- Developer Assertio Therapeutics
- Class Antiarrhythmics; Ischaemic heart disorder therapies
- Mechanism of Action Calcium channel antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Angina pectoris; Arrhythmias; Immunological disorders
Most Recent Events
- 02 Jul 2003 AIT 100 is available for licensing (http://www.spectrumpharm.com)
- 02 Jul 2003 Discontinued - Preclinical for Angina pectoris in USA (unspecified route)
- 02 Jul 2003 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)